<DOC>
	<DOCNO>NCT02731287</DOCNO>
	<brief_summary>Infantile hemangioma ( IH ) common benign vascular tumor pediatric population . Oral propranolol treatment choice complicate hemangioma . Topical timolol , non-selective beta-blocker , emerge treatment report effective safe treatment IH , especially superficial hemangioma . Investigators hypothesize treatment topical timolol first two month life , proliferative phase early proliferative phase , may prevent grow need treat oral propranolol .</brief_summary>
	<brief_title>Topical Timolol Infantile Hemangioma Early Proliferative Phase</brief_title>
	<detailed_description>A multicentric , randomize , double-blind , placebo-controlled , phase II clinical trial evaluate efficacy safety 0.5 % timolol maleate solution early treatment infantile hemangioma . Patients less 60 day life focal segmental hemangioma , superficial , mixed abortive treat topical timolol 0.5 % twice day 24 week . Changes lesion size , color thickness evaluate photograph take 2,4,8,12,24 36 week . Vital sign side effect record visit . Response treatment evaluate blinded investigator semiquantitative scale ( complete resolution , improve , stabilization , worsen ) .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Written inform consent study participation use patient 's photographs patient 's parent ( ) guardian ( ) , The patient 10 60 day age time enrollment , The patient : least one focal segmental hemangioma , mixed superficial , present anywhere body least 0.3 cm minimum diameter great 5 cm . abortive minimal growth hemangioma Infantile hemangioma precursor Patients &gt; 60 day age Complicated hemangioma ( lifethreatening , functionthreatening , ulcerate ) Children previously receive systemic , intralesional topical corticosteroid , imiquimod , vincristine , alphainterferon , propranolol beta blocker , PDL laser . Patients PHACES , LUMBAR , SACRAL PELVIS syndrome . Internal involvement hemangioma ( liver , GI tract , larynx ) Children personal history asthma cardiac condition may predispose heart block . Children congenital birth defect Children Cancer ( leukemia , sarcoma , neuroblastoma , retinoblastoma ) Children history hypersensitivity beta blocker excipients .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>